Derma Sciences Inc.
Second-quarter losses soar for Derma Sciences
Second-quarter losses soared for Derma Sciences (NSDQ:DSCI), but the wound care company still managed to beat Wall Street’s earnings expectations by 4¢.
Princeton, N.J.-based Derma Sciences reported losses of $7.3 million, or 43¢ per share, on sales of $18.1 million for the 3 months ended June 30. Losses grew 59.8% despite a 3.1% top-line gain, compared with Q2 2012.
Derma Sciences skins out $36M
Derma Sciences (NSDQ:DSCI) said it’s closed an offering of some 3.5 million shares of its stock at $10.34 apiece.
The Princeton, N.J.-based medical device company said it plans to use the $33.8 million in net proceeds from the $36.4 million offering to further develop its lead drug candidate DSC127.
Derma Sciences said the drug is being designed to treat chronic diabetic foot ulcers.
Derma Sciences wins CE Mark for honey-based wound dressing | Regulatory Roundup
Derma Sciences CEO Quilty’s resignation from board appeases Nasdaq | Wall Street Beat
Derma Sciences (NSDQ:DSCI) president & CEO Edward Quilty resigned from the company’s board of directors, settling a non-compliance issue that could have led to delisting from the Nasdaq stock exchange.
Stryker to begin New York layoffs ahead of the medical device tax | Wall Street Beat
Bruker names Charles Wagner Jr. CFO | Personnel Moves
Riding high, Intuitive Surgical is poised to dazzle again with Q1 numbers| Wall Street Beat
A week after posting an all-time stock high, Intuitive Surgical (NSDQ:ISRG) is poised to bedazzle Wall Street for the 12th straight quarter tomorrow.
Boston Scientific launches Pluromed’s BackStop kidney stone treatment | Wall Street Beat
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
Fujifilm closes $1B SonoSite deal | Wall Street Beat
Fujifilm Holdings (TSE:4901) said it closed its $54-per-share acquisition of SonoSite (NSDQ: SONO).